Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer

被引：0
|
作者：
Rodriguez Garces, Maria Yeray
Garcia Samblas, Victoria
Morales Pancorbo, David
Bayo Calero, Juan Lucas
机构：
[1] Hosp Juan Ramon Jimenez, Huelva, Spain
[2] Juan Ramon Jimenez Hosp, Huelva, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12612
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of Anlotinib based neoadjuvant chemotherapy for locally advanced triple negative breast cancer (TNBC)
    Ren, Kuojun
    Wang, Shuhan
    Ye, Tingbo
    Zhu, Zhengzhi
    Hong, Shikai
    Wang, Shengying
    Liu, Jianjun
    BMC CANCER, 2024, 24 (01)
  • [42] Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)
    Schneeweiss, A.
    Chia, S.
    Hickish, T.
    Harvey, V.
    Eniu, A.
    Hegg, R.
    Tausch, C.
    Seo, J. H.
    Tsai, Y. -F.
    Ratnayake, J.
    McNally, V.
    Ross, G.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2013, 24 (09) : 2278 - 2284
  • [43] Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer
    Yu, Anthony F.
    Singh, Jasmeet C.
    Wang, Rui
    Liu, Jennifer E.
    Eaton, Anne
    Oeffinger, Kevin C.
    Steingart, Richard M.
    Hudis, Clifford A.
    Dang, Chau T.
    ONCOLOGIST, 2017, 22 (06): : 642 - 647
  • [44] Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients
    Gianmaria Miolo
    Elena Muraro
    Debora Martorelli
    Davide Lombardi
    Simona Scalone
    Simon Spazzapan
    Samuele Massarut
    Tiziana Perin
    Elda Viel
    Elisa Comaro
    Renato Talamini
    Ettore Bidoli
    Elisa Turchet
    Diana Crivellari
    Riccardo Dolcetti
    BMC Cancer, 14
  • [45] Neoadjuvant pembrolizumab plus decitabine followed by standard neoadjuvant chemotherapy for locally advanced HER2-breast cancer
    Bear, Harry Douglas
    Idowu, Michael O.
    Poklepovic, Andrew
    Sima, Adam
    Kmieciak, Maciej
    CANCER RESEARCH, 2020, 80 (04)
  • [46] Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer
    Jiang, M.
    Chai, Y.
    Liu, J.
    He, M.
    Zhang, M.
    Zhou, S.
    Xu, B.
    Li, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S353 - S353
  • [47] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [48] Efficacy of dose-dense and anthracycline-free regimens in neoadjuvant chemotherapy of HER2-positive breast cancer: a single-center matched-cohort study. Preliminary results
    Kovalenko, Elena
    Zhulikov, Yaroslav
    Khoroshilov, Maxim
    Vorotnikov, Igor
    Petrovskiy, Alexander
    Artamonova, Elena
    CANCER RESEARCH, 2024, 84 (09)
  • [49] Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer
    Xie, Yifan
    Wu, Siyu
    Zhang, Ying
    Li, Jianwei
    Mo, Miao
    Shao, Zhimin
    Liu, Guangyu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
12345